School of Medicine
Showing 4,141-4,160 of 13,030 Results
-
David Ross Ha
Lecturer, Medicine - Med/Infectious Diseases
BioDr. David Ha, PharmD is Lecturer with the Stanford University School of Medicine Division of Infectious Diseases and Geographic Medicine and Manager of Antimicrobial Stewardship at Stanford Health Care in Stanford, California. Dr. Ha's professional interests include mentorship of trainees, antimicrobial stewardship, and quality improvement.
Publications: https://www.ncbi.nlm.nih.gov/myncbi/david.ha.3/bibliography/public/ -
Richard Haarburger
Postdoctoral Scholar, General Internal Medicine
BioRichard Haarburger is a postdoctoral scholar in the Department of Medicine (Primary Care and Population Health) at Stanford University, working in the lab of Pascal Geldsetzer. He studies questions at the intersection of epidemiology, health policy, and applied econometrics, with a focus on causal inference in large real-world health datasets.
His current work uses quasi-experimental and survival analysis methods to evaluate how preventive interventions (e.g. herpes zoster vaccinations) affect neurological outcomes such as dementia incidence at the population level. He also develops empirical strategies for dealing with challenges common in observational health data, including treatment effect heterogeneity, incomplete outcome follow-up, and competing risks.
Richard’s broader research interests include impact evaluation methods, causal machine learning, and the health and economic consequences of new technologies. During his PhD in quantitative economics, he worked on measurement bias in health surveys, high-dimensional forecasting, and heterogeneity in technology adoption. -
Beth Habelow
Lecturer, Surgery - Anatomy
BioPhysical therapist, lecturer
-
Pardes Habib
Instructor, Neurosurgery
BioPardes Habib, MD/PhD, is an Instructor in the Department of Neurosurgery at Stanford University School of Medicine. His research focuses on how human neural stem cells (hNSCs) drive brain repair after chronic stroke. By integrating state-of-the-art imaging (MRI/PET) with spatially resolved multi omics, he maps structural and molecular remodeling after stroke and aims to identify diagnostic and prognostic biomarkers that drive the development and refinement of precision, cell-based therapies.
Dr. Habib completed dual doctorates in Neurology/Neuroscience (MD/PhD) and Biochemistry (PhD) at RWTH Aachen University in Germany, where he later earned a Habilitation (Venia Legendi) in Experimental Neurology—an academic qualification comparable to an associate professorship.
As head of Aachen’s Translational Stroke Research Group, he investigated neuroprotective and neuroinflammatory pathways and illuminated the roles of inflammasome activation and the unfolded protein response in acute ischemic stroke.
Since joining Dr. Gary Steinberg’s laboratory at Stanford in 2022, Dr. Habib has focused on decoding the molecular crosstalk among hNSCs, immune cells, and host neural circuits. His long-term goal is to transform these insights into targeted interventions that restore function and quality of life for patients living with the aftermath of stroke. -
Frezghi Habte
Director, Stanford Center for Innovations in In vivo Imaging (SCi3), Stanford Center for Innovation and In Vivo Imaging
Current Role at StanfordDirector, Stanford Center for Innovation, in In vivo Imaging
-
Laura Michele Hack
Assistant Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)
BioDr. Laura M. Hack is an Assistant of Psychiatry and Behavioral Sciences at Stanford University and the Veterans Affairs Palo Alto Health Care System (PAVAHCS). As Associate Director of the Novel & Precision Neurotherapeutics Program at the Stanford Center for Precision Mental Health, Dr. Hack leads a translational, patient-centered research group that designs and implements mechanistic clinical trials for biologically informed subtypes of Mood, Anxiety, and Trauma-related Disorders (MATRDs).
Her work spans repurposed pharmacologic interventions (e.g., guanfacine), neuromodulation techniques (e.g., repetitive transcranial magnetic stimulation [TMS]), and therapies involving altered states of consciousness (i.e., ketamine, MDMA, psilocybin, and anesthesia-induced dreaming). Across these modalities, Dr. Hack's focus is on tailoring treatment based on objective, biologically anchored markers that match the patient’s profile.
Dr. Hack also directs the Stanford Precision Psychiatry Clinic, a high-touch, high-tech consultation service designed to support individuals with a primary diagnosis of major depression and often comorbid MATRDs. This clinic integrates the investigational use of high-definition neuroimaging (personalized brain circuit scores) with symptom profiling, neurocognitive testing, pharmacogenomic analysis, inflammatory biomarkers, and standard blood work. The aim is to generate individualized insights that inform treatment decisions and help patients better understand the biological underpinnings of their condition—often reducing self-blame and empowering engagement in care.
In her role as Deputy Director as well as Ketamine and Education Lead of the Precision Neuromodulation Clinic (PNC) at PAVAHCS, Dr. Hack specializes in delivering evidence-based, FDA-cleared interventions including TMS and intranasal ketamine for Veterans experiencing treatment-resistant depression, frequently in the context of comorbid PTSD. -
Francois Haddad
Clinical Professor, Medicine - Cardiovascular Medicine
BioDr. Francois Haddad, MD is a Clinical Professor of Medicine that specializes in the field of cardio-vascular imaging, pulmonary hypertension, advanced heart failure and transplantation. Dr. Haddad has over 18 years of practice in the field of cardiology. He directs Stanford Cardiovascular Institute Biomarker and Phenotypic Core Laboratory dedicated to translational studies in cardiovascular medicine. The laboratory focuses on (1) identifying early biomarkers of heart failure and aging, (2) bioengineering approaches to cardiovascular disease modeling and (3) novel informatic approach for the detection and risk stratification of disease. He is involved is several precision medicine initiatives in health including the Project Baseline, the Integrated Personalized Omics Profiling Initiative, the Athletic screening program at Stanford and the Strong-D cardiac rehabilitation initiative in individuals with diabetes mellitus.
